The information presented on this website, including but not limited to any forward-looking statements, forecasts, or business projections, is for informational purposes only and are based upon various assumptions, and these assumptions may prove to be incorrect. These forward-looking statements, forecasts, and business projections are based on current expectations and assumptions which may change over time due to various market factors, economic conditions, and business decisions. Actual results may differ materially from those expressed or implied in any projections or forecasts. They should not be construed as financial or investment advice. We make no guarantees regarding the performance or outcomes described and do not assume nor accept any responsibility for the accuracy or completeness of these statements and we do not accept liability for any loss or damages that may arise from reliance on this information. You are encouraged to perform your own due diligence and consult with a qualified financial advisor before making any business or investment decisions.
*The testimonials provided through this website are given by investors who have invested cash into Endless Corporation in exchange for securities of the company, and they are offering such testimonials in their individual capacity. Such persons have not received and will not receive in the future compensation for providing such testimonials.
Reg A
**In no way limiting the foregoing, any reference to any objective, goal, intention, or plan of Endless Corporation becoming, emulating, or operating in a similar manner as Fortune 100 and 500 companies is not a guarantee that it will be able to do so, or will not elect to do otherwise, now or in the future. In addition, while this website may reference aspirations of Endless Corporation for a future public listing, it is still formulating and has not yet decided on or yet implemented a plan to achieve such result. Future results are not guaranteed, nor is how, the capability to achieve such results, and no investment decision should be based upon the potential of a future public listing, or any other potential future event discussed herein.
These offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
Please note investors in this offering will be clients of the issuer and not Dalmore Group, LLC ("Dalmore"), a registered broker-dealer and member FINRA/SIPC. Dalmore's role in the transaction is to facilitate back-office and regulatory functions related to the Regulation A transaction, and acts only as the broker/dealer of record for the offering listed. Dalmore is not providing investment advice or recommendations, or legal or tax advice.
This Reg A investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. All investors should make their own determination, with the assistance of their own financial or other advisors, as to whether or not to make any investment, based on their own independent evaluation, analysis, and circumstances.
No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. An offering statement regarding this offering has been filed with the SEC. You may obtain a copy of the preliminary offering circular that is part of that offering statement. Form 1-A Filing with SEC
Endless Biotech is building an autonomous plant production platform where robotics, artificial intelligence, tissue culture, and CRISPR converge to target a $15.5 trillion market.
Capital Raised
Plants Produced
Pipeline
Cost Reduction via Automation
Trusted Technology Partners
Investor Voices
Real investors. Real conviction. Tap any video to hear their story.
Caylee Orsinger
Investor
David Posner
Investor
Alex Turrow
Investor
Micah Perini
Investor
Reggie Booker
Investor
Cassidy Yazzie
Investor
Mike Noshay
Investor
Teddy Pillay
Investor
Caylee Orsinger
Investor
David Posner
Investor
Alex Turrow
Investor
Micah Perini
Investor
Reggie Booker
Investor
Cassidy Yazzie
Investor
Mike Noshay
Investor
Teddy Pillay
Investor
The Thesis
01 / 05
Robotics + AI + tissue culture + CRISPR in one integrated system. Endless is building the category for industrial-scale plant production.
Only
Integrated Platform
Our system learns from every production cycle—improving contamination detection, refining protocols, and increasing propagation success rates over time.
24/7
Autonomous Monitoring
Gross margin of 86% improving to 89.6% at scale driven by robotics. At scale, our cost per clone targets $0.78, positioning Endless among the most cost-efficient producers in the market.
86% → 89.6%
Gross Margin Expansion
Agriculture’s starting material layer remains fragmented across controlled crops, ornamentals, forestry, and food crops. Endless is building an integrated platform combining tissue culture, robotics, and AI to deliver pure genetics, consistent plant production at scale.
$15.5T
Total Addressable Market
Endless is building the production infrastructure for clean plant genetics at industrial scale, positioning the company for long-term participation in the public markets.
Global
Infrastructure Platform

The Problem
0–40%
of global crop production destroyed annually by pests, disease, contamination, and climate variability.
FAO — Plant Production and Protection
The $15.5 trillion global agriculture economy depends on plant genetics that are often unverified, uncleaned, and inconsistent. Inconsistent plant genetics compound these challenges, making significant losses inevitable in traditional agricultural systems.
Our Technology
Four integrated technologies. One autonomous system.
24/7 Lights-Out Production
An autonomous plant production system designed for agricultural biotech. Standard Bots integration targets 68% labor cost reduction while increasing consistency to near-perfect levels.
Capabilities
Pipeline
Identified Opportunities
Plants Produced
And Delivered
Facility
Operational in Tulsa
The Platform
Learn how robotics, AI, and tissue culture converge into the world’s of autonomous plant production system.

“Everyone talks about AI and robotics transforming agriculture. But automation cannot fix unhealthy plants. Agriculture must start with clean, verified genetics. That’s where Endless begins—using tissue culture, automation, and data to produce healthy plant material at scale.”
Market Opportunity
$15.5 Trillion
Total Addressable Market
Agriculture’s starting material layer remains fragmented across every crop vertical. Endless is building an integrated platform combining tissue culture, robotics, and AI.
$80B+
76 countries legalized
$55B+
Global floriculture
$340B+
Reforestation demand
$15T+
Global agriculture
Revenue Engine
Six diversified revenue streams. From production to software.
Economics
5-Year Revenue Trajectory
Automation reduces labor cost by 68%
Revenue / Clone
Cost / Clone
Gross Profit / Clone
Gross Margin
Latest
Key milestones and developments.
Press
Strategic partnerships and milestones.
Strategic partnership integrates advanced sensors and real-time environmental monitoring for data-driven cultivation management.
Joint marketing campaign showcases the combined expertise in dehumidification technology and precision cannabis cultivation.
Rigorous R&D testing validates Grodan Rockwool as the preferred growing medium, enabling superior crop steering and standardized cultivation.
Global strategic cross-marketing partnership aims to enhance brand visibility and open new markets across the cannabis industry.
FOHSE A3i 1500-watt lighting technology selected for superior canopy penetration and multi-spectrum control in R&D operations.
Strategic partnership integrates advanced sensors and real-time environmental monitoring for data-driven cultivation management.
Joint marketing campaign showcases the combined expertise in dehumidification technology and precision cannabis cultivation.
Rigorous R&D testing validates Grodan Rockwool as the preferred growing medium, enabling superior crop steering and standardized cultivation.
Global strategic cross-marketing partnership aims to enhance brand visibility and open new markets across the cannabis industry.
FOHSE A3i 1500-watt lighting technology selected for superior canopy penetration and multi-spectrum control in R&D operations.
The Path Forward
From foundation to global leadership.
Building I operational. Reg D raise. Team scaling. 40K clones/mo.
40K / moBuilding II construction. Reg A+ filing. Full robotics deployment.
5M / mo targetOrnamentals, forestry, food crops. Revenue acceleration. AI platform licensing.
$72M revenueMulti-facility operations. $300M+ revenue target. Public markets.
IPOInternational expansion. Full autonomous operations. Market leadership.
$334M+Defensibility
An engineering moat, not a business moat.
Tissue culture formulations, growth media, genetic protocols. The science foundation.
FOHSE lighting, PIPP vertical racking, Quest climate, AROYA monitoring. Purpose-built for autonomous operation.
Standard Bots partnership. Custom hardware–software integration designed to automate key production workflows and improve scale and consistency.
Plant Health AI trained on millions of data points. Contamination detection, growth optimization, predictive maintenance.
Every batch feeds the AI. Every cycle improves the models. This advantage widens with time.
Documented, repeatable processes for autonomous production. The operating system for plant biotech.
$10M+ raised, $150M pathway, operational facility, $120M+ pipeline. Each milestone strengthens the position.
Infrastructure
This is what a robotics and AI facility looks like when the product is biology.
23,196
Square Feet
40K
Clones / Month
24/7
Autonomous Operation
Tulsa, OK
Location


















Large Scale
Facility
5M+
Clones / Month Target
Full
Robotics From Day One
Our investor portal contains everything you need: full financials, data room, research docs, facility assessments, and team profiles. Every number sourced. Every claim documented.
18 data room documents · 5-year financial model · 22 research reports
The Team
The people building the future of agriculture.

CEO & Chairman
Built Endless from concept to $10M+ raised, 25+ employees, $120M+ pipeline

Lab Director

Technical Lead

Chief of Staff

Head of Sales

Plant Specialist

Head of Education

Endless Biotech is building an autonomous production platform where robotics and AI produce verified, disease-free plants at a scale and consistency designed to exceed traditional methods. Every clone we produce is a step toward food security, agricultural resilience, and a smarter planet.
Endless Biotech is currently raising under Reg D 506(c) via convertible notes with 8% interest and a 25–50% conversion discount. A Reg A+ Tier 2 offering at $1.00/share is pending SEC qualification.
Minimum investment details are available in the investor portal. Current offering is open to accredited investors under Reg D 506(c).
Our Reg A+ Tier 2 offering is pending SEC qualification. Once qualified, it will be open to both accredited and non-accredited investors at $1.00/share.
Revenue grew from $488K (2023) to $1.25M (2024), representing 157% year-over-year growth. FY2025 reached approximately $1.8M in total revenue, with an $11M three-year purchase agreement supporting the pipeline.
Enter our investor portal to review the full data room, financial projections, and team profiles. When you’re ready, the “Ready to Invest” button will connect you with our investor relations team.